Clinical Trial Update: A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 clinical trial update for TY101 evaluating safety and efficacy in locally advanced/metastatic solid tumors and relapsed or refractory lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Lymphomas
• Solid Tumors

Drugs mentioned

• TY101

Snippet

Sponsor: Tayu Huaxia Biotech Medical Group Co., Ltd. | Conditions: Locally Advanced /Metastatic Solid Tumors, Relapsed or Refractory Lymphomas | Phase 1, Phase 2 | Status: UNKNOWN